08.06.26 -- The CDMO Perspective On Breaking Down Development Silos In Vivo CGT

Animal‑free raw materials offer adjustable attributes, controlled manufacturing, and consistent nutrient profiles, ensuring reliable performance and customizable solutions across multiple production processes.

Understanding when to leverage GMP vs non-GMP stability studies and where each approach delivers maximum value can help sponsors make better development decisions and reach clinic faster.

Assessing bispecific antibody quality requires advanced testing to catch mispaired species, evaluate structural integrity, and verify therapeutic potency for clinical safety.

A high‑throughput, automated RNA‑seq workflow maintains uniform gene‑expression profiles across wide RNA inputs, enabling consistent library quality and scalable genomics on standard liquid‑handling platforms.

Optimizing DNA inputs is key to scaling AAV therapies. Discover how cell-free enzymatic methods can cut costs up to 22%, saving millions annually at commercial scale.

Accurate AAV capsid ratios are critical to gene therapy efficacy. See how mass photometry delivers faster, lower-cost E/F analysis with single-particle resolution.

Explore how structured process development enables scalable GMP adenovirus manufacturing with optimized performance, yield, and control at large scale.